Preventing Perinatal Depression
Center M Feasibility and Efficacy Pilot Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health & Science University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- gestational age at intervention onset between 12 and 30 weeks
- English fluency
- no previous experience in a mindfulness-based intervention group
- ability and willingness to participate in a telehealth intervention
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Center M Intervention
Data from participants in this arm will be compared across pre-intervention, post-intervention, and 6-weeks postpartum.
All participants will receive the Center M intervention, which includes group-based Cognitive Behavioral Therapy (CBT) sessions and home practice materials.
|
Center M consists of weekly, 1-hour, telehealth, mindfulness-based Cognitive Behavioral Therapy (CBT) group sessions for four consecutive weeks.
Participants joined group sessions on their personal computer, tablet, or phone.
Each visit involved the introduction of a core mental well-being theme, learning skills to develop non-judgmental self-awareness and/or cognitive reappraisal skills, skills practice, and discussion of home practice materials.
Home practice materials included written mindful awareness instructions, audio-guided meditations, self-compassion exercises, and practices in recognizing the interrelationships between thoughts, feelings, and behaviors.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Edinburgh Postnatal Depression Scale (EPDS)
Time Frame: Measured at pre-intervention (within 1 week before first session), post-intervention (within 1 week after last session), and 6-weeks postpartum
|
10-item self-report measure used to assess perinatal depression symptomology over the past seven days.
|
Measured at pre-intervention (within 1 week before first session), post-intervention (within 1 week after last session), and 6-weeks postpartum
|
|
Patient Health Questionnaire - 8 (PHQ-8)
Time Frame: Measured at pre-intervention (within 1 week before first session), post-intervention (within 1 week after last session), and 6-weeks postpartum
|
Self-report measure that assesses depressive symptoms over the past two weeks.
|
Measured at pre-intervention (within 1 week before first session), post-intervention (within 1 week after last session), and 6-weeks postpartum
|
|
Five Facets of Mindfulness Questionnaire (FFMQ)
Time Frame: Measured at pre-intervention (within 1 week before first session) and 6-weeks postpartum
|
39-item self-report measure to assess mindfulness skills.
|
Measured at pre-intervention (within 1 week before first session) and 6-weeks postpartum
|
|
Emotional Regulation Questionnaire (ERQ)
Time Frame: Measured at pre-intervention (within 1 week before first session) and 6-weeks postpartum
|
10-item self-report measure used to assess one's ability to regulate or manage emotion using cognitive reappraisal and expressive suppression.
|
Measured at pre-intervention (within 1 week before first session) and 6-weeks postpartum
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
ERQ Cognitive Reappraisal Subscale
Time Frame: Measured at pre-intervention (within 1 week before first session) and 6-weeks postpartum
|
6 items to reflect cognitive reframing or restructuring.
|
Measured at pre-intervention (within 1 week before first session) and 6-weeks postpartum
|
|
ERQ Expressive Suppression Subscale
Time Frame: Measured at pre-intervention (within 1 week before first session) and 6-weeks postpartum
|
4 items to reflect expressive suppression.
|
Measured at pre-intervention (within 1 week before first session) and 6-weeks postpartum
|
|
Center M Satisfaction
Time Frame: Post-intervention (within 1 week after last session)
|
60 minute telehealth format focus groups including open-ended questions about their experience with Center M or two-question survey with a Likert scale satisfaction question and a free text question.
|
Post-intervention (within 1 week after last session)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Ellen Tilden, PhD, CNM, FACNM, Oregon Health and Science University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- OHSU IRB 24818
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.